MTOR and colorectal cancer: Given the finding that the PI3K complex may be a key signaling network orchestrator of colorectal cancer metastasis, therapeutics targeting PI3K/AKT or the downstream mTOR complex [17] might be rational, and within this frame of reference, the ex vivo phosphosubstrate technology could show useful in developing the required biomarkers of signaling pathway druggability.